Summary

HIV Diagnostics Market Growth & Trends

The global HIV diagnostics market size is estimated to reach USD 1.55 billion by 2030, expanding at a CAGR of 5.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Key factors accounting for the growth of this market include the growing need in for the development of more sensitive HIV diagnostic point of care tests which can be easily implemented at the location of patient care in resource-limited settings. Technological development of tests which is expected to introduce a number of novel rapid, point-of-care tests throughout the forecast period is a primary factor expected to fuel the growth of the HIV diagnostics market. Furthermore, government programs and campaigns initiated against HIV, global healthcare efforts to reduce disease incidence, and the presence of high unmet demand in the Middle Eastern and Eastern regions of the market are some key factors expected to serve as lucrative future growth opportunities.

HIV Diagnostics Market Report Highlights

• The antibody test segment dominated the industry and accounted for the largest revenue share of 56.6% in 2024. This large share can be accounted for by the high market usage and penetration rates of these tests which include, ELISA, home access dried blood spot, western blot testing IFA, and RIPA. These tests are highly sensitive and accurate and thus are most commonly used for screening and confirmation of HIV-1 & HIV-2.

• Viral Load testing and CD4 testing also accounted for a considerable share of the market in 2024. There is a prevalent in the market for the development of these tests which will make them more sensitive, rapid in nature, and portable to the point of care to enhance their market usability and accessibility in resource-limited HIV-affected regions.

• It is expected that during the forecast period, a number of novel point-of-care HIV diagnostic products will be commercialized which are currently under clinical development and in product pipelines of key market players. This increase in the range of products is expected to fuel the growth of this market over the forecast period.

• The Asia Pacific HIV diagnostics industry is expected to experience a notable growth rate during the forecast period. Advancements in research and development in the region are significant drivers for the HIV diagnostics market.

• The Latin America HIV diagnostics industry is expected to experience significant growth throughout the forecast period. The HIV diagnostics market is driven by the region's progress in reducing HIV-related deaths, which have declined by 28% in Latin America and 57% in the Caribbean over the past decade.

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Mode
1.2.3. Test Type
1.2.4. End Use
1.2.5. Regional scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Mode outlook
2.2.3. Test type outlook
2.2.4. End Use outlook
2.2.5. Regional outlook
2.3. Competitive Insights
Chapter 3. HIV Diagnostics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Advancements in Diagnostic Technologies
3.2.1.2. Government Initiatives to Increase Accessibility
3.2.1.3. Rising HIV Awareness and Screening Programs
3.2.2. Market restraint analysis
3.2.2.1. High Cost of Advanced Diagnostics
3.2.2.2. Stigma and Social Barriers
3.3. HIV Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. HIV Diagnostics Market: Product Estimates & Trend Analysis
4.1. Product Market Share, 2024 & 2030
4.2. Segment Dashboard
4.3. Global HIV Diagnostics Market by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Consumables
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Instruments
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Software and Services
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. HIV Diagnostics Market: Mode Estimates & Trend Analysis
5.1. Mode Market Share, 2024 & 2030
5.2. Segment Dashboard
5.3. Global HIV Diagnostics Market by Mode Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Self-test
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Lab-based
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. HIV Diagnostics Market: Test Type Estimates & Trend Analysis
6.1. Test Type Market Share, 2024 & 2030
6.2. Segment Dashboard
6.3. Global HIV Diagnostics Market by Test Type Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Antibody Test
6.4.1.1. HIV-1 Screening Tests
6.4.1.1.1. ELISA/EIA
6.4.1.1.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
6.4.1.1.2. Home Access Dried Blood Spot
6.4.1.1.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
6.4.1.1.2.2. Market estimates and forecasts 2018 to 2030 (USD million)
6.4.1.1.3. Rapid Tests (Dot plot, Agglutination Tests)
6.4.1.1.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
6.4.1.2. HIV-1 Antibody Confirmatory Tests
6.4.1.2.1. Western Blot Test
6.4.1.2.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
6.4.1.2.2. Indirect Immunofluorescent Antibody Assay (IFA)
6.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
6.4.1.2.3. Line Immunoassay
6.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
6.4.1.2.4. RadioImmunoPrecipitation Assay (RIPA)
6.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
6.4.1.3. HIV-2 & Group O Diagnostic Tests
6.4.1.3.1. Blood Antibody Tests
6.4.1.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
6.4.1.3.2. Dried Blood Spot (DBS) Test
6.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
6.4.1.3.3. Others and (Oral, Urine)
6.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
6.4.2. Viral load test
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
6.4.3. CD4 test
6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
6.4.4. Others
6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
Chapter 7. HIV Diagnostics Market: End Use Estimates & Trend Analysis
7.1. End Use Market Share, 2024 & 2030
7.2. Segment Dashboard
7.3. Global HIV Diagnostics Market by End Use Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.4.1. Diagnostic Laboratories
7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
7.4.2. Hospitals & Clinics
7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
7.4.3. Home Settings
7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
Chapter 8. HIV Diagnostics Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2024 & 2030
8.2. Regional Market Dashboard
8.3. Global Regional Market Snapshot
8.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
8.5. North America
8.5.1. U.S.
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework/ reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. Target disease prevalence
8.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
8.5.2. Canada
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework/ reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. Target disease prevalence
8.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
8.5.3. Mexico
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework/ reimbursement structure
8.5.3.3. Competitive scenario
8.5.3.4. Target disease prevalence
8.5.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million
8.6. Europe
8.6.1. UK
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/ reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. Target disease prevalence
8.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
8.6.2. Germany
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. Target disease prevalence
8.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
8.6.3. France
8.6.3.1. Key country dynamics
8.6.3.2. Regulatory framework/ reimbursement structure
8.6.3.3. Competitive scenario
8.6.3.4. Target disease prevalence
8.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
8.6.4. Italy
8.6.4.1. Key country dynamics
8.6.4.2. Regulatory framework/ reimbursement structure
8.6.4.3. Competitive scenario
8.6.4.4. Target disease prevalence
8.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
8.6.5. Spain
8.6.5.1. Key country dynamics
8.6.5.2. Regulatory framework/ reimbursement structure
8.6.5.3. Competitive scenario
8.6.5.4. Target disease prevalence
8.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
8.6.6. Norway
8.6.6.1. Key country dynamics
8.6.6.2. Regulatory framework/ reimbursement structure
8.6.6.3. Competitive scenario
8.6.6.4. Target disease prevalence
8.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
8.6.7. Sweden
8.6.7.1. Key country dynamics
8.6.7.2. Regulatory framework/ reimbursement structure
8.6.7.3. Competitive scenario
8.6.7.4. Target disease prevalence
8.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
8.6.8. Denmark
8.6.8.1. Key country dynamics
8.6.8.2. Regulatory framework/ reimbursement structure
8.6.8.3. Competitive scenario
8.6.8.4. Target disease prevalence
8.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
8.7. Asia Pacific
8.7.1. Japan
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/ reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. Target disease prevalence
8.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
8.7.2. China
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. Target disease prevalence
8.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
8.7.3. India
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/ reimbursement structure
8.7.3.3. Competitive scenario
8.7.3.4. Target disease prevalence
8.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
8.7.4. Australia
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/ reimbursement structure
8.7.4.3. Competitive scenario
8.7.4.4. Target disease prevalence
8.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
8.7.5. South Korea
8.7.5.1. Key country dynamics
8.7.5.2. Regulatory framework/ reimbursement structure
8.7.5.3. Competitive scenario
8.7.5.4. Target disease prevalence
8.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
8.7.6. Thailand
8.7.6.1. Key country dynamics
8.7.6.2. Regulatory framework/ reimbursement structure
8.7.6.3. Competitive scenario
8.7.6.4. Target disease prevalence
8.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
8.8. Latin America
8.8.1. Brazil
8.8.1.1. Key country dynamics
8.8.1.2. Regulatory framework/ reimbursement structure
8.8.1.3. Competitive scenario
8.8.1.4. Target disease prevalence
8.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
8.8.1.6. )
8.8.2. Argentina
8.8.2.1. Key country dynamics
8.8.2.2. Regulatory framework/ reimbursement structure
8.8.2.3. Competitive scenario
8.8.2.4. Target disease prevalence
8.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
8.9. MEA
8.9.1. South Africa
8.9.1.1. Key country dynamics
8.9.1.2. Regulatory framework/ reimbursement structure
8.9.1.3. Competitive scenario
8.9.1.4. Target disease prevalence
8.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
8.9.2. Saudi Arabia
8.9.2.1. Key country dynamics
8.9.2.2. Regulatory framework/ reimbursement structure
8.9.2.3. Competitive scenario
8.9.2.4. Target disease prevalence
8.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
8.9.3. UAE
8.9.3.1. Key country dynamics
8.9.3.2. Regulatory framework/ reimbursement structure
8.9.3.3. Competitive scenario
8.9.3.4. Target disease prevalence
8.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
8.9.4. Kuwait
8.9.4.1. Key country dynamics
8.9.4.2. Regulatory framework/ reimbursement structure
8.9.4.3. Competitive scenario
8.9.4.4. Target disease prevalence
8.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Vendor Landscape
9.3.1. Key company market share analysis, 2024
9.3.2. Alere Inc.
9.3.2.1. Company overview
9.3.2.2. Financial performance
9.3.2.3. Product benchmarking
9.3.2.4. Strategic initiatives
9.3.3. Abbott
9.3.3.1. Company overview
9.3.3.2. Financial performance
9.3.3.3. Product benchmarking
9.3.3.4. Strategic initiatives
9.3.4. Bristol-Myers Squibb Company
9.3.4.1. Company overview
9.3.4.2. Financial performance
9.3.4.3. Product benchmarking
9.3.4.4. Strategic initiatives
9.3.5. Janssen Global Services, LLC
9.3.5.1. Company overview
9.3.5.2. Financial performance
9.3.5.3. Product benchmarking
9.3.5.4. Strategic initiatives
9.3.6. Gilead Sciences, Inc.
9.3.6.1. Company overview
9.3.6.2. Financial performance
9.3.6.3. Product benchmarking
9.3.6.4. Strategic initiatives
9.3.7. Merck & Co. Inc.
9.3.7.1. Company overview
9.3.7.2. Financial performance
9.3.7.3. Product benchmarking
9.3.7.4. Strategic initiatives
9.3.8. VIIV Healthcare
9.3.8.1. Company overview
9.3.8.2. Financial performance
9.3.8.3. Product benchmarking
9.3.8.4. Strategic initiatives
9.3.9. BD
9.3.9.1. Company overview
9.3.9.2. Financial performance
9.3.9.3. Product benchmarking
9.3.9.4. Strategic initiatives
9.3.10. Beckman Coulter, Inc.
9.3.10.1. Company overview
9.3.10.2. Financial performance
9.3.10.3. Product benchmarking
9.3.10.4. Strategic initiatives
9.3.11. Sysmex Europe SE
9.3.11.1. Company overview
9.3.11.2. Financial performance
9.3.11.3. Product benchmarking
9.3.11.4. Strategic initiatives
9.3.12. Apogee Flow Systems
9.3.12.1. Company overview
9.3.12.2. Financial performance
9.3.12.3. Product benchmarking
9.3.12.4. Strategic initiatives
9.3.13. Point Care
9.3.13.1. Company overview
9.3.13.2. Financial performance
9.3.13.3. Product benchmarking
9.3.13.4. Strategic initiatives
9.3.14. Zyomtronix, Inc.
9.3.14.1. Company overview
9.3.14.2. Financial performance
9.3.14.3. Product benchmarking
9.3.14.4. Strategic initiatives
9.3.15. Mylan N.V.
9.3.15.1. Company overview
9.3.15.2. Financial performance
9.3.15.3. Product benchmarking
9.3.15.4. Strategic initiatives
9.3.16. F. Hoffmann-La Roche Ltd.
9.3.16.1. Company overview
9.3.16.2. Financial performance
9.3.16.3. Product benchmarking
9.3.16.4. Strategic initiatives
9.3.17. Siemens Healthcare GmbH
9.3.17.1. Company overview
9.3.17.2. Financial performance
9.3.17.3. Product benchmarking
9.3.17.4. Strategic initiatives
9.3.18. QIAGEN
9.3.18.1. Company overview
9.3.18.2. Financial performance
9.3.18.3. Product benchmarking
9.3.18.4. Strategic initiatives